Caspase-3 Controls Aml1-Eto-Driven Leukemogenesis Via Autophagy Modulation In A Ulk1-Dependent Manner
Na Man,Yurong Tan,Xiao-Jian Sun,Fan Liu,Guoyan Cheng,Sarah M. Greenblatt,Camilo Martinez,Daniel L. Karl,Koji Ando,Ming Sun,Dan Hou,Bingyi Chen,Mingjiang Xu,Feng-Chun Yang,Zhu Chen,Saijuan Chen,Stephen D. Nimer,Lan Wang
DOI: https://doi.org/10.1182/blood-2016-10-745034
IF: 20.3
2017-01-01
Blood
Abstract:AML1-ETO (AE), a fusion oncoprotein generated by t(8; 21), can trigger acute myeloid leukemia (AML) in collaboration with mutations including c-Kit, ASXL1/2, FLT3, N-RAS, and K-RAS. Caspase-3, a key executor among its family, plays multiple roles in cellular processes, including hematopoietic development and leukemia progression. Caspase-3 was revealed to directly cleave AE in vitro, suggesting that AE may accumulate in a Caspase-3-compromised background and thereby accelerate leukemogenesis. Therefore, we developed a Caspase-3 knockout genetic mouse model of AML and found that loss of Caspase-3 actually delayed AML1-ETO9a (AE9a)-driven leukemogenesis, indicating that Caspase-3 may play distinct roles in the initiation and/or progression of AML. We report here that loss of Caspase-3 triggers a conserved, adaptive mechanism, namely autophagy (or macroautophagy), which acts to limit AE9a-driven leukemia. Furthermore, we identify ULK1 as a novel substrate of Caspase-3 and show that upregulation of ULK1 drives autophagy initiation in leukemia cells and that inhibition of ULK1 can rescue the phenotype induced by Caspase-3 deletion in vitro and in vivo. Collectively, these data highlight Caspase-3 as an important regulator of autophagy inAMLand demonstrate that the balance and selectivity between its substrates can dictate the pace of disease.